Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aroa BiosurgeryASX:ARX 62 Return-on-Tangible-Asset is 12.36% as of Mar. 2026. GuruFocus rates ASX:ARX with a GF Score™ of 62/100 and a GF Value™ of A$0.81 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 856 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 64.84% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Aroa Biosurgery's annualizedNet Income for the quarter that ended in Mar. 2026 was A$10.08 Mil. Aroa Biosurgery's average total tangible assets for the quarter that ended in Mar. 2026 was A$81.57 Mil. Therefore, Aroa Biosurgery's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 12.36%.
The historical rank and industry rank for Aroa Biosurgery's Return-on-Tangible-Asset or its related term are showing as below:
ASX:ARX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -25.4 Med: -6.86 Max: 4.78
Current: 4.78
During the past 7 years, Aroa Biosurgery's highest Return-on-Tangible-Asset was 4.78%. The lowest was -25.40%. And the median was -6.86%.
ASX:ARX's Return-on-Tangible-Asset is ranked better than 64.84% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs ASX:ARX: 4.78
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Aroa Biosurgery Return-on-Tangible-Asset Related Terms
Aroa Biosurgery Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ARX vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Aroa Biosurgery's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.36% mean?
Aroa Biosurgery (ASX:ARX) has a Return-on-Tangible-Asset of 12.36% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #301 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 35.2%.
Is Aroa Biosurgery's Return-on-Tangible-Asset too high?
Aroa Biosurgery's current Return-on-Tangible-Asset is 12.36%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Aroa Biosurgery's value of 12.36% is 1977.3% above this industry median. Based on the distribution chart, Aroa Biosurgery ranks #301 out of 856 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #301 out of 856 companies for Return-on-Tangible-Asset. This puts Aroa Biosurgery in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.60. Aroa Biosurgery's value of 12.36% is 1977.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current Return-on-Tangible-Asset of 12.36% is 1977.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current Return-on-Tangible-Asset is 12.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.81, compared to a current price of A$0.60 — trading 25.9% below its estimated fair value. The current Return-on-Tangible-Asset is 12.36% and 1977.3% above the Medical Devices & Instruments industry median of 0.60. Aroa Biosurgery's overall GF Score™ is 62/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Return-on-Tangible-Asset is 12.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.60 is trading 25.9% below its estimated GF Value™ of A$0.81.
GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.
Key valuation signals for ASX:ARX:
Return-on-Tangible-Asset: 12.36%
GF Value™: A$0.81 vs. price of A$0.60 (25.9% below fair value)
Industry Position: 1977.3% above the Medical Devices & Instruments median (#301 of 856)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score
Get the complete analysis for ASX:ARX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
